AI Article Synopsis
- Radiation therapy has been a key treatment for Hodgkin lymphoma (HL), but its role has shifted with the rise of effective systemic therapies and awareness of long-term side effects.
- Modern treatment often combines chemotherapy with involved site radiation therapy (ISRT) for optimal patient outcomes, focusing on reducing long-term toxicity while still aiming for effective survival rates.
- This review discusses the evidence supporting the use of radiotherapy in HL and explores techniques to minimize late adverse effects from treatment.
Article Abstract
Radiation therapy has historically been the pillar of curative treatment for Hodgkin lymphoma (HL). With improved efficacy of systemic therapy and the ever-increasing recognition of treatment-related morbidity in long-term survivors, the role of radiotherapy has evolved significantly. Modern combined modality therapy (CMT) with multi-agent chemotherapy followed by involved site radiation therapy (ISRT) to initially involved sites of disease remains the gold standard for the majority of patients with HL. Reduction of long-term treatment-related toxicity has become the major driver in clinical trial design for early-stage HL while improved disease-specific survival remains the goal in patients with more advanced and unfavorable disease. This review will address the data supporting the use of radiotherapy in HL as well as specific methods for reducing late toxicity from radiotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11899-017-0385-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!